Skip to main content
SMFM 2026 Pregnancy Meeting Main banner
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Presentation Icons
Additional registration fee required
Additional registration fee required
Faculty have requested this content not be shared outside of the session
Faculty have requested this content not be shared outside of the session
CME Credit Offered
CME Credit Offered
Abstract Award
Abstract Award
Recording available 2/16-5/2
Recording available 2/16-5/2
AIUM Credit
AIUM Credit
Foundation Awardee
Foundation Awardee
Poster Icons
Abstract Award
Abstract Award
Foundation Awardee
Foundation Awardee

Poster Session 1

Category: Hypertension

Poster Session 1

(252) Implementation of sFlt-1/PlGF testing among hospitalized patients with hypertensive disorders: impact on healthcare utilization

Wednesday, February 11, 2026
10:30 AM - 12:00 PM  
Objective:
In 2023, the FDA approved a sFlt-1/PlGF test for risk assessment of preeclampsia with severe features (PS). We implemented this test on our antepartum unit in March 2024. Due to the high negative predictive value of this test, we tested the hypothesis that availability of sFlt-1/PlGF testing reduces avoidable healthcare utilization.

Study Design:
This is a pre-post cohort study of all patients admitted to a single center to rule out PS. Patients on therapeutic anticoagulation, younger than 18, multifetal gestations, and without delivery information were excluded. The primary outcome was gestational latency (duration from HDP admission to delivery). Secondary outcomes included number and duration of antepartum hospitalizations as well as readmission within 6 weeks postpartum. Outcomes were compared between the pre-implementation cohort (2/1/2023-2/29/2024) and post-implementation cohort (3/1/2024-4/1/2025). Segmented regression-based approaches were used to assess association between pre- and post-cohorts with each outcome, adjusting for potentially unbalanced confounders. For the number of antepartum hospitalizations, a non-parametric bootstrap resampling method was applied.

Results:
98 patients were admitted to rule out PS in the pre-cohort and 73 in the post-cohort. In the post-cohort, 21 (28%) had sFlt-1/PlGF testing. The incidence of PS or eclampsia in the pre- and post-cohorts was 76.0% and 73.6%, respectively (p=0.72). sFlt-1/PlGF testing was more frequently ordered among patients with chronic hypertension (p=0.015). The availability of sFlt-1/PlGF testing was not associated with a difference in gestational latency, even when the analysis was restricted to those who had sFlt-1/PlGF testing sent. There was no difference in number or duration of antepartum admissions or postpartum readmission.

Conclusion:
The availability of sFlt-1/PlGF testing was not associated with a difference in gestational latency or hospital utilization in this cohort. This may be related to low uptake of the test (< 30%) and calls for future work studying barriers to uptake and management plans based on results.